Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Boehringer Ingelheim announced it will establish a new biopharmaceutical production facility in Vienna.

Boehringer Ingelheim to Establish Biopharmaceutical Production Facility in Vienna

Synpromics announced collaborations with Avalanche Biotechnologies and Applied Genetic Technologies Corporation to use synthetic promoters to develop gene therapies, including adeno-associated virus technology for treating eye diseases.

Synpromics Collaborates on Gene Therapies

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Collaboration between users and suppliers to increase understanding, clearly define user requirements, and mitigate risk is facilitating acceptance by industry and regulators.

Overcoming Challenges in Implementing Single-Use Systems

Millipore Express PHF hydrophilic, sterilizing-grade filters from EMD Millipore offer faster flow rates to speed the process or reduce the process footprint.

Single-Use Membrane Filters Offer Fast Flow Rates

PSL has installed several advanced contained filtration and drying facilities as part of an expansion of a pharmaceutical manufacturing plant in Singapore.

PSL Completes Advanced Process Installations for Pharmaceutical Manufacturing in Singapore

Sandoz announces that the European Medicines Agency has accepted a MAA for a biosimilar of etanercept.

EMA Accepts Sandoz’s Biosimilar for Etanercept

Seqirus, CSL Limited’s influenza vaccine business, announced the opening of their corporate headquarters in the United Kingdom.

Seqirus Opens Corporate Headquarters in the United Kingdom

James E. Akers is the president of Akers Kennedy & Associates, PO Box 22562, Kansas City, MO 64113, akainckc@aol.com.

James P. Agalloco is the president of Agalloco & Associates, P.O. Box 899, Belle Mead, NJ 08502, tel. 908.874.7558, jagalloco@aol.com. He is also a member of Pharmaceutical Technology’s editorial advisory board.

Microorganism lethality requirements for process validation must always be balanced with the need to protect product integrity and patient safety.

Achieving Balance in Sterile Product Manufacturing

Analytical methods and functional assays are used to compare molecules and relate characteristics to quality attributes.

Determining Biosimilarity

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

The advantages of fixed-dose combinations are well recognized but their formulation and manufacture can be a challenge, Stefania Barzanti from IMA Active explains why.